The Avanzar study could read out shortly.
ApexOnco Front Page
Recent articles
Satri-cel is filed for gastric cancer approval in China.
Approval decisions await Ono and SpringWorks, while key data approach for Pfizer and Arvinas’s SERD.
Felmetatug vedotin’s exit could be bad news for Mersana.
AstraZeneca bags three of the month’s four oncology approvals.
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Firce-1 is scrapped after showing dismal response rates and patient deaths.
On a wing and a prayer Leap heads for phase 3.
